Trial reportJournal of the American Society of Nephrology : JASN2026
Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial.
Trial report in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04170543. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects With Diabetic Kidney Disease
Open the trial in the graphWho cites it
2 citing papers in PubMed.
- Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program.Biologics : targets & therapy · 2026Article
- Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Journal of endocrinological investigation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
key pointsIn 558 adults with type 2 diabetes and CKD, inhibition of IL-33 by tozorakimab was well tolerated. IL-33 signaling was blocked at all doses, eosinophil counts decreased, and urinary CC-chemokine ligand 2 decreased at the high dose versus placebo. No significant differences in urinary albumin-creatinine ratio were observed between placebo and tozorakimab on top of standard of care.
backgroundIn patients with type 2 diabetes and CKD, elevated inflammatory biomarkers are associated with adverse kidney outcomes. IL-33 contributes to glomerular endothelial inflammation in diabetic kidney disease (DKD). This study evaluated the therapeutic potential of tozorakimab, an IL-33-neutralizing mAb, in DKD.
methodsFRONTIER-1 ( NCT04170543 ) was a phase 2b, randomized, double-blind, placebo-controlled trial including adults with type 2 diabetes, an eGFR of 25-75 ml/min per 1.73 m 2 , urinary albumin-creatinine ratio (UACR) of 100-3000 mg/g, and maximally tolerated renin-angiotensin-aldosterone system blocker therapy. Participants received tozorakimab (30, 60, 120, or 300 mg) or placebo every 28 days for 168 days. All participants received dapagliflozin during days 85-168. The primary end point was UACR change on treatment from baseline to day 169 (per-protocol population). Exploratory end points included inflammatory biomarkers linked to IL-33 activity.
resultsAmong 558 randomized participants (mean [SD] age 67 [10] years, 30% female, mean [SD] eGFR 48 [15] ml/min per 1.73 m 2 , geometric mean UACR 460 mg/g), tozorakimab ( N =425) was well tolerated with no safety concerns identified. In the per-protocol population ( N =465), IL-33 signaling was inhibited by >95% across all doses, eosinophil counts decreased by >19%, and urinary CC-chemokine ligand 2 levels were significantly decreased by 29% with the 300 mg dose (two-sided 90% confidence intervals, 14% to 42%) versus placebo. However, no statistically significant differences in UACR were observed between placebo (-22%) and treatment (-23% to -25%).
conclusionsTozorakimab effectively inhibited IL-33 signaling but did not reduce UACR compared with placebo in patients with DKD over 24 weeks. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT04170543.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.